DXB

1.28%

38.5¢ dimerix limited

Ann: AGM Presentation, page-48

First 48 Last

Share
Profile

Follow
singhgu

2,011 Posts.

455

03/01/24

10:12

Post #: 71704402
Share

Originally posted by singhgu: ↑

"yes yes I know it's on top of angiotensin blocker and compared to placebo."

Its not Yes Yes Einstien...The whole premise of DMX-200 is add on to the standard of care so its an added benefit to the patient that's why you simply can't say 17%. We are not sparsentan (stand alone therapy), we are an add on drug and if you have again bothered to read archives, potential of Dimerix to work in conjunction with Sparsentan is possible as well.

In terms to your statistical significance of P value...Now I know its a term widely used statistical measure...

But I will also add is that a lower P value doesnt necessarily mean that the drug works and same goes for vice versa. You will be surprised to see how many drugs how many drugs at different P values end up getting a completely different final outcome...

The other thing I will add is that at such a low sample size, p value sort of become less relevant...

I think the other poster like you quoted Opthea P2 magnificent results...You and him/her may want to also check the history of Fovista...

Finally, you may want to check who Dr Hiddo Heerspink and David Packham are before you come here and throw garbage out.

Now does this mean, I am 100% sure that the trial outcome is a definite success, absolutely NO.

But investing is about risk reward as NO one, even smart A$$ like you can predict the final outcome (Many drugs with amazing P2 results fail P3, again look up Fovista as someone mentoned Opthea)...We may not make great returns on this drug but atleast most made their initial investment back by buying and selling at the right time...

P.S.: Since the time you came on this forum and trying to find a reason why you don't want to invest, you could have pretty much doubled your money in the last 2 weeks if you keep things simple and went with risk/reward...Not that smart I guess..

Now go fly Kites

Expand

Completely forgot to add that I am certain there are more qualified and experienced statisticians with a proper background in R&D in Advanz Pharma than random posters on HotCopper.

The other random poster gave this a 50% chance of failure, technically a 50% chance of success... at 50% chance of success with 100mil market cap... I say an absolute steal with 50% probability of this becoming another NEU...

DXB Price at posting: 24.0¢ Sentiment: Buy Disclosure: Held
11 Upvote

1 Great analysis

Reply

Top Stories

The market's shrugged at China's stimulus measures all year. Why is this one different?

The winners & losers on market if negative gearing were gone

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

DEG

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

KAL

KalGold rolls out detailed aeromagnetic survey across Pinjin project

NAM

ACCC seeks Olam divestments before it can buy Namoi Cotton

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

ESR

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

STK

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

There are more pages in this discussion • 30 more messages in this thread...

First 48 Last

Add DXB (ASX) to my watchlist

(20min delay)
Last 38.5¢		Change -0.005(1.28%)		Mkt cap ! $214.4M

Open	High	Low	Value	Volume
39.0¢	39.0¢	37.0¢	$503.5K	1.322M

Buyers (Bids)

No.	Vol.	Price($)
2	26318	38.0¢

Sellers (Offers)

Price($)	Vol.	No.
39.0¢	170072	6

View Market Depth

No.	Vol.	Price($)
1	1318	0.380
3	72579	0.375
4	134161	0.370
1	30000	0.365
4	27499	0.360

Price($)	Vol.	No.
0.390	140963	5
0.395	61740	2
0.400	115000	2
0.405	86528	4
0.410	56400	2

Last trade - 16.10pm 27/09/2024 (20 minute delay)

DXB (ASX) Chart

Ann: AGM Presentation, page-48

The market's shrugged at China's stimulus measures all year. Why is this one different?

The winners & losers on market if negative gearing were gone

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

KalGold rolls out detailed aeromagnetic survey across Pinjin project

ACCC seeks Olam divestments before it can buy Namoi Cotton

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: AGM Presentation, page-48

Top Stories

The market's shrugged at China's stimulus measures all year. Why is this one different?

The winners & losers on market if negative gearing were gone

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

KalGold rolls out detailed aeromagnetic survey across Pinjin project

ACCC seeks Olam divestments before it can buy Namoi Cotton

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News